Judy Triplett
University of KentuckyLexington, United States
339720 RESULTS
University of KentuckyLexington, United States
COMMENT Having been involved in many clinical trials in AD from both the academic (investigator) and industry (sponsor) perspective, this is a long overdue and necessary debate. As many have pointed out, the poor track record of clinical trials aimed at modulatin
COMMENT The new reports by Kim et al. are very intriguing, as they provide evidence that contradicts over a decade of research indicating that ApoE is required for Aβ deposition. Given the novelty of these results, a primary concern is that the authors establish
COMMENT Kim et al. have given us an important insight into the relationship between plasma ApoE levels and Alzheimer’s disease pathogenesis that, as the authors point out, will drive therapeutic strategies in a 180-degree different direction than currently envisa
COMMENT This study indicates the effectiveness of AV45 PET for presymptomatic diagnosis of AD. 0 saido
COMMENT I would wonder whether addressing mitochondrial function, one of the earliest events in ALS (presymptomatic), would be overwhelmed by other factors driving disease once symptomatic and, hence, diagnosable with current methods. I am in the camp of neuroinf
COMMENT The thoughtful commentary by Sperling, Jack, and Aisen focused on their third hypothesis, i.e., that AD trials have failed because the drugs are being administered at the wrong stage of the disease. They examined this hypothesis exclusively from the amylo
PAPER Ahlskog JE, Geda YE, Graff-Radford NR, Petersen RC
PAPER Oulhaj A, Wilcock GK, Smith AD, de Jager CA
AbbVieNorth Chicago, United States
PAPER Doraiswamy PM, Xiong GL
PAPER Pagnoni G, Cekic M
PAPER Sonntag WE, Goliszek AG, Brodish A, Eldridge JC
PAPER Sapolsky RM, Krey LC, McEwen BS
PAPER Budas G, Coughlan CM, Seckl JR, Breen KC
No filters selected